A “Disclosure Defense” in Liability Law

In this time of liability reform, pharma deserves the chance to align its economic interests with its ethical obligations to the patient.

Related Content:

Process and ScalingQuality SystemsPharmaceutical Technology-03-02-2005

A CDMO’s Role in API Quality

FDA Grants Fast Track Designation to Teva Celiac Disease Candidate

GSK, Spero Therapeutics Oral UTI Treatment Trial Stopped Early for Efficacy